WO2023076419A3 - Anticorps de sars-cov-2 et méthodes d'utilisation - Google Patents

Anticorps de sars-cov-2 et méthodes d'utilisation Download PDF

Info

Publication number
WO2023076419A3
WO2023076419A3 PCT/US2022/047926 US2022047926W WO2023076419A3 WO 2023076419 A3 WO2023076419 A3 WO 2023076419A3 US 2022047926 W US2022047926 W US 2022047926W WO 2023076419 A3 WO2023076419 A3 WO 2023076419A3
Authority
WO
WIPO (PCT)
Prior art keywords
libraries
antibodies
cov
methods
sars
Prior art date
Application number
PCT/US2022/047926
Other languages
English (en)
Other versions
WO2023076419A2 (fr
Inventor
Aaron Sato
Tom YUAN
Ana LUJAN
Original Assignee
Twist Bioscience Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Twist Bioscience Corporation filed Critical Twist Bioscience Corporation
Publication of WO2023076419A2 publication Critical patent/WO2023076419A2/fr
Publication of WO2023076419A3 publication Critical patent/WO2023076419A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des méthodes et des compositions se rapportant à des bibliothèques d'anticorps optimisés. Les banques selon la présente invention comprennent des acides nucléiques codant des anticorps du SARS-CoV-2 ou ACE2. La présente invention concerne en outre des banques de protéines générées lorsque les banques d'acides nucléiques sont traduites. La présente invention concerne en outre des banques de cellules exprimant des banques d'acides nucléiques variées.
PCT/US2022/047926 2021-10-27 2022-10-26 Anticorps de sars-cov-2 et méthodes d'utilisation WO2023076419A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163272642P 2021-10-27 2021-10-27
US63/272,642 2021-10-27

Publications (2)

Publication Number Publication Date
WO2023076419A2 WO2023076419A2 (fr) 2023-05-04
WO2023076419A3 true WO2023076419A3 (fr) 2023-09-28

Family

ID=86158733

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/047926 WO2023076419A2 (fr) 2021-10-27 2022-10-26 Anticorps de sars-cov-2 et méthodes d'utilisation

Country Status (1)

Country Link
WO (1) WO2023076419A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150087819A1 (en) * 2007-08-23 2015-03-26 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
US20200325235A1 (en) * 2019-02-26 2020-10-15 Twist Bioscience Corporation Variant nucleic acid libraries for glp1 receptor
US20210292393A1 (en) * 2020-03-09 2021-09-23 Abcellera Biologics Inc. Anti-Coronavirus Antibodies and Methods of Use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150087819A1 (en) * 2007-08-23 2015-03-26 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
US20200325235A1 (en) * 2019-02-26 2020-10-15 Twist Bioscience Corporation Variant nucleic acid libraries for glp1 receptor
US20210292393A1 (en) * 2020-03-09 2021-09-23 Abcellera Biologics Inc. Anti-Coronavirus Antibodies and Methods of Use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE PROTEIN ANONYMOUS : "Chain B, Nanobody", XP093043563, retrieved from NCBI *
DATABASE PROTEIN ANONYMOUS : "immunoglobulin heavy chain junction region, partial [Homo sapiens]", XP093096948, retrieved from NCBI *

Also Published As

Publication number Publication date
WO2023076419A2 (fr) 2023-05-04

Similar Documents

Publication Publication Date Title
WO2021222315A3 (fr) Bibliothèques d'acides nucléiques variants de coronavirus
WO2023023183A3 (fr) Anticorps sars-cov-2, compositions associées et méthodes d'utilisation
WO2022271884A3 (fr) Méthodes et compositions se rapportant à des épitopes d'anticorps contre le covid
WO2023023190A3 (fr) Anticorps à domaine unique anti-sars-cov-2
WO2005121331A3 (fr) Polypeptides galnact2 tronques et acides nucleiques
WO2021119193A3 (fr) Bibliothèques de variants d'acides nucléiques pour les récepteurs d'adénosine
WO2006083276A3 (fr) Polypeptides et conjugues interferon-alpha
WO2005121332A3 (fr) Polypeptides st6galnacl tronques et acides nucleiques
WO2005113592A3 (fr) Polypeptides et conjugues interferon-alpha
ZA200405390B (en) Entrapped binding proteins as biosensors
WO2004003147A3 (fr) Polypeptides cngh0004, anticorps, compositions, procedes et utilisations
WO2007044083A3 (fr) Polypeptides d'interferon-alpha mis au point genetiquement
WO2006073429A3 (fr) Protéines de liaison piégées utiles comme biocapteurs
WO2002066653A3 (fr) Banques procaryotiques et leurs utilisations
WO2004015070A3 (fr) Isolation et identification de cellules t
WO2006113475A3 (fr) Procedes et compositions pour moduler l'adhesion et la resistance au stress chez des bacteries
WO2002101056A3 (fr) Isomerase d'acide linoleique conjugue et procede de production de cet acide linoleique conjugue
WO2003042401A3 (fr) Nouveaux chromophores/fluorophores et leurs procedes d'utilisation
WO2004007664A3 (fr) Vecteurs d'acides nucleiques
ATE337336T1 (de) Nukleinsäuren, die für stichodactylidae chromoproteine kodieren
WO2023076419A3 (fr) Anticorps de sars-cov-2 et méthodes d'utilisation
WO2021197401A8 (fr) Polypeptide de liaison à l'antigène se liant à cd47, et son utilisation
WO2004056965A3 (fr) Acides nucleiques codant des cibles de medicaments antifongiques et leurs procedes d'utilisation
DE69333304D1 (de) Erhöhte produktion von sekretierten proteinen durch rekombinante eukaryotische zellen
WO2023091614A3 (fr) Anticorps variants dickkopf-1 et procédés d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22888138

Country of ref document: EP

Kind code of ref document: A2